Back to top
more

Insmed (INSM)

(Real Time Quote from BATS)

$109.75 USD

109.75
814,122

-1.51 (-1.36%)

Updated Aug 7, 2025 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Implied Volatility Surging for Insmed (INSM) Stock Options

Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

Zacks Equity Research

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 4.71% and 20.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for May 1st

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 1st

Zacks Equity Research

Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Options Traders Expect Huge Moves in Insmed (INSM) Stock

Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

Zacks Equity Research

Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce

Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).

    Zacks Equity Research

    Is the Options Market Predicting a Spike in Insmed (INSM) Stock?

    Investors need to pay close attention to Insmed Incorporated (INSM) stock based on the movements in the options market lately.

      Zacks Equity Research

      Insmed (INSM): Moving Average Crossover Alert

      Insmed Incorporated (INSM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

        Zacks Equity Research

        New Strong Sell Stocks for March 1st

        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

          Zacks Equity Research

          Implied Volatility Surging for Insmed Incorporated (INSM) Stock Options

          Insmed Incorporated (INSM) needs investors to pay close attention to the stock based on moves in the options market lately.

            Sweta Killa headshot

            Best Sector ETF of Q3 and its Top-Performing Stocks

            Inside the top performing stocks of top U.S.-focused ETF of Q3.

              Zacks Equity Research

              Company News For Sep 6, 2017

              Companies in the news are: INSM,CLLS,FUL,GOOGL

                Zacks Equity Research

                Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%

                Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data

                  Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.

                    Ryan McQueeney headshot

                    Why Did Insmed (INSM) Stock Skyrocket Today?

                    Shares of Insmed Inc. (INSM) more than doubled in pre-market trading Tuesday after the company announced that its new drug, an inhaled antibiotic known as Alis, successfully treated patients with a rare lung disease.

                      Zacks Equity Research

                      Options Traders Expect Huge Moves in Insmed (INSM) Stock

                      Investors in Insmed (INSM) need to pay close attention to the stock based on moves in the options market lately.

                        Zacks Equity Research

                        Are Options Traders Betting on a Big Move in Insmed (INSM) Stock?

                        Investors in Insmed (INSM) need to pay close attention to the stock based on moves in the options market lately.

                          Zacks Equity Research

                          Implied Volatility Surging For Insmed, Inc. (INSM) Stock Options

                          Implied Volatility Surging For Insmed, Inc. (INSM) Stock makes it lucrative to the Option traders.

                            Zacks Equity Research

                            Options Traders Expect Huge Moves in Insmed (INSM) Stock

                            Insmed (INSM) needs Investors to pay close attention to the stock based on moves in the options market lately.

                              Zacks Equity Research

                              Implied Volatility Surging for Insmed (INSM) Stock Options

                              Insmed (INSM) warrants investors' attention based on moves in the options market lately.

                                Zacks Equity Research

                                Do Options Traders Know Something About Insmed Incorporated (INSM) Stock We Don't?

                                Options traders are pricing in a big move for Insmed Incorporated (INSM) shares as it has huge implied volatility.